Journal article
A review of the first year of Medicare coverage of erythropoietin.
- Abstract:
-
Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD). In a study of rHuEPO diffusion, costs, and effectiveness, we analyze ESRD program data and all claims submitted to Medicare for reimbursement of rHuEPO administered to ESRD dialysis patients. Access to rHuEPO was rapid and extensive during the first year of Medicare coverage. Dosing of rHuEPO and achieved hematocrit were lower than expected based on the results of clinic...
Expand abstract
Actions
Authors
Bibliographic Details
- Journal:
- Health care financing review
- Volume:
- 15
- Issue:
- 3
- Pages:
- 83-102
- Publication date:
- 1994-01-01
- EISSN:
-
1554-9887
- ISSN:
-
0195-8631
- Source identifiers:
-
359135
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:359135
- UUID:
-
uuid:6995474b-037d-4e1f-87ff-2837af53bde3
- Local pid:
- pubs:359135
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 1994
If you are the owner of this record, you can report an update to it here: Report update to this record